At the time of writing, CRISPR Therapeutics AG [CRSP] stock is trading at $73.07, down -2.47%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CRSP shares have gain 7.87% over the last week, with a monthly amount glided 30.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on September 18, 2025, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $70. Previously, Evercore ISI upgraded its rating to Outperform on February 14, 2025, and elevated its price target to $99. On February 12, 2025, upgrade upgraded it’s rating to Hold but maintained its price target of $35 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $65 on February 03, 2025. Needham reiterated its recommendation of a Buy and reduced its price target to $84 on August 06, 2024. Rodman & Renshaw started tracking with a Buy rating for this stock on August 02, 2024, and assigned it a price target of $90.
For the past year, the stock price of CRISPR Therapeutics AG fluctuated between $30.04 and $78.48. Currently, Wall Street analysts expect the stock to reach $99.31 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $73.07 at the most recent close of the market. An investor can expect a potential return of 35.91% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
According to CRISPR Therapeutics AG [NASDAQ:CRSP], the company’s sales were 38.05M for trailing twelve months, which represents an 72.53% jump. Gross Profit Margin for this corporation currently stands at -2.17% with Operating Profit Margin at -12.21%, Pretax Profit Margin comes in at -12.42%, and Net Profit Margin reading is -12.52%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.25 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that CRISPR Therapeutics AG [NASDAQ:CRSP] has a current ratio of 16.61. As well, the Quick Ratio is 16.61, while the Cash Ratio is 1.89. Considering the valuation of this stock, the price to sales ratio is 174.66, the price to book ratio is 3.77.
Transactions by insiders
Recent insider trading involved Kulkarni Samarth, Chief Executive Officer, that happened on Aug 18 ’25 when 13081.0 shares were sold. Director, Treco Douglas A completed a deal on Aug 06 ’25 to buy 20000.0 shares. Meanwhile, Director George Simeon bought 0.99 million shares on Jul 16 ’25.
